Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015, Article ID 629046, 4 pages
http://dx.doi.org/10.1155/2015/629046
Case Report

Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma

1Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, Italy
2Department of Radiology, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, Italy
3Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, Italy

Received 17 September 2015; Revised 15 November 2015; Accepted 30 November 2015

Academic Editor: Jorg Kleeff

Copyright © 2015 Michela Roberto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Bianchi, M. Sun, C. Jeldres et al., “Distribution of metastatic sites in renal cell carcinoma: a population-based analysis,” Annals of Oncology, vol. 23, no. 4, pp. 973–980, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Motzer, J. Bacik, L. H. Schwartz et al., “Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 22, no. 3, pp. 454–463, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. O. Bennani, S. Derrey, O. Langlois et al., “Brain metastasis from renal cell carcinoma,” Neurochirurgie, vol. 60, no. 1-2, pp. 12–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Shuch, J. C. La Rochelle, T. Klatte et al., “Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival,” Cancer, vol. 113, no. 7, pp. 1641–1648, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. P. Sheehan, M.-H. Sun, D. Kondziolka, J. Flickinger, and L. D. Lunsford, “Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control,” Journal of Neurosurgery, vol. 98, no. 2, pp. 342–349, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Y. C. Heng, T. K. Choueiri, B. I. Rini et al., “Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials,” Annals of Oncology, vol. 25, no. 1, pp. 149–154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. D. A. Bastos, A. M. Molina, V. Hatzoglou et al., “Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis,” Clinical Genitourinary Cancer, vol. 13, no. 1, pp. 59–66, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Verma, E. Jonasch, P. K. Allen et al., “The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma,” American Journal of Clinical Oncology, vol. 36, no. 6, pp. 620–624, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. J. Motzer, B. Escudier, S. Oudard et al., “Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors,” Cancer, vol. 116, no. 18, pp. 4256–4265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Di Lorenzo, C. Buonerba, P. Federico et al., “Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma,” European Urology, vol. 58, no. 6, pp. 906–911, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Y. C. Heng, C. Wells, F. Donskov et al., “Third-line therapy in metastatic renal cell carcinoma: results from the International mRCC Database Consortium,” Journal of Clinical Oncology, vol. 33, supplement 7, abstract 430, 2015. View at Google Scholar
  12. R. J. Motzer, C. Porta, N. J. Vogelzang et al., “Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomized phase 3 trial,” The Lancet Oncology, vol. 15, no. 3, pp. 286–296, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Iacovelli, G. Cartenì, C. N. Sternberg et al., “Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort,” European Journal of Cancer, vol. 49, no. 9, pp. 2134–2142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Blesius, B. Beuselinck, C. Chevreau et al., “Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 trial,” Clinical Genitourinary Cancer, vol. 11, no. 2, pp. 128–133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Busch, C. Seidel, B. Erber et al., “Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma,” European Urology, vol. 64, no. 1, pp. 62–70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Grünwald, C. Seidel, M. Fenner, A. Ganser, J. Busch, and S. Weikert, “Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies,” British Journal of Cancer, vol. 105, no. 11, pp. 1635–1639, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Escudier, T. Eisen, W. M. Stadler et al., “Sorafenib in advanced clear-cell renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 2, pp. 125–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Bracarda, M. Sisani, F. Marrocolo, A. Hamzaj, S. del Buono, and V. De Simone, “GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer,” Critical Reviews in Oncology/Hematology, vol. 89, no. 3, pp. 386–393, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. S. K. Pal, D. M. S. Hossain, Q. Zhang et al., “Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile,” The Journal of Urology, vol. 193, no. 4, pp. 1114–1121, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. M. R. Matrana, C. Duran, A. Shetty et al., “Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies,” European Journal of Cancer, vol. 49, no. 15, pp. 3169–3175, 2013. View at Publisher · View at Google Scholar · View at Scopus